Drug - Rasuvo™ (methorexate for subcutaneous injection) [Medac Pharma Inc.]
April 2015
Therapeutic area - Rheumatoid arthritis; polyarticular juvenile idiopathic arthritis; psoriasis
Approval will only be granted for diagnoses of rheumatoid arthritis; polyarticular juvenile idiopathic arthritis (pJIA); severe, disabling psoriasis.
Rheumatoid Arthritis, pJIA approval criteria:
Psoriasis approval criteria:
Strength | Quantity limit per 28 days |
7.5 mg/0.15 ml | 0.6 ml |
10 mg/0.2 ml | 0.8 ml |
12.5 mg/0.25 ml | 1 ml |
15 mg/0.3 ml | 1.2 ml |
17.5 mg/0.35 ml | 1.4 ml |
20 mg/0.4 ml | 1.6 ml |
22.5 mg/0.45 ml | 1.8 ml |
25 mg/0.5 ml | 2 ml |
27.5 mg/0.55 ml | 2.2 ml |
30 mg/0.6 ml | 2.4 ml |
Rasuvo™ will only be authorized for approved FDA indications.
MHCP Provider Call Center 651-431-2700 or 800-366-5411